Short Description
Quantifies IDH activity via NADH/NADPH production.
Development Stage
Research-Grade Metabolic Assay Development
Description
The OXPHOSight™ Isocitrate Dehydrogenase Assay Kit measures IDH activity, which is critical for screening inhibitors of IDH1/2 mutants in acute myeloid leukemia research. This assay supports the development of targeted cancer therapies by validating the blockade of oncometabolite production. It provides kinetic data on enzyme function, helping to characterize the potency and selectivity of novel IDH inhibitors.
Features
Measures IDH activity; Critical for screening IDH1/2 mutant inhibitors in acute myeloid leukemia research.
Process Relevance
Oncology Target Validation (AML)
Application Stage
Target Validation
Applications
Investigation of IDH mutations in glioma and leukemia.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Absorbance at 565 nm
Sample Type
Plasma, serum, tissue and culture media, samples
Research Areas
Oncology; Metabolic Disease
Datasheet